deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04442048

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO)

COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

Sponsor: ATGen Canada Inc

Updated 24 times since 2020 Last updated: Dec 22, 2025 Started: Oct 1, 2020 Primary completion: May 7, 2024 Completion: Dec 22, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04442048, this PHASE3 trial focuses on Cancer and Covid-19 and remains completed. Sponsored by ATGen Canada Inc, it has been updated 24 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~May 2022 · 11 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

24 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  3. May 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

Show 19 earlier versions
  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  8. May 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  10. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  11. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  12. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  13. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  14. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  15. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  16. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  17. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  18. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE3

  19. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ATGen Canada Inc
  • BioCan Rx
  • Canadian Cancer Society (CCS)
  • Canadian Cancer Trials Group
  • Canadian Centre for Applied Research in Cancer Control (ARCC)
  • Immodulon Therapeutics Ltd
  • Ontario Institute for Cancer Research
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .